Michelle Merchant retweeted
Join us at #TCT2025 for an amazing learning opportunity with expert speakers Daniel Burkhoff, MD, Brian Kolski, MD, Ramesh Mazhari, MD.
Our teams at #JNJ are working to take on heart disease and drive better outcomes for patients. See some of the latest advancements we’re working on. #MyCompany bit.ly/3VU0cTP
Michelle Merchant retweeted
Need a refresher on Impella best practices for shock management in the post-DanGer era?
Download Dr. Navin Kapur's presentation from TCT: bit.ly/4ltO1aZ
Michelle Merchant retweeted
Today we celebrate an important and exciting milestone as the PROTECT IV study completes enrollment with 1252 subjects randomized!
This achievement would not have been possible without the support of each PROTECT IV site. We value and appreciate your collective contributions to advance clinical evidence of protected PCI, with this randomized trial being the largest of its kind in the history of interventional cardiology.
Michelle Merchant retweeted
What is Protected PCI?
Dr. Chuck Simonton explains what a Protected PCI with Impella is and who may benefit from receiving this procedure: bit.ly/3GawBAW
Michelle Merchant retweeted
Today, @ACCinTouch and @AHAScience released treatment guideline changes for acute coronary syndrome and cardiogenic shock.
The guideline update relies on the DanGer Shock RCT, the landmark trial on Impella that published in the New England Journal of Medicine, to come to its recommendation.
Access the guideline here: bit.ly/41md07V
@JACCJournals
#ClinicalGuidelines #JACC
🆕 2025 ACC/AHA/ACEP/NAEMSP/SCAI ACS Guideline highlights the importance of the most recent clinical evidence in treating patients w/ heart attacks and other #cvACS.
Access the guideline here: bit.ly/41md07V
@JACCJournals #ClinicalGuidelines #JACC
Michelle Merchant retweeted
Today, Johnson & Johnson MedTech, the global leader in heart recovery, is proud to celebrate the inaugural National Heart Recovery Awareness Day!
Recognized through a U.S. Congressional resolution, this designation will help increase awareness of heart health and how innovative medical technology helps patients return home to their families – with their native heart.
In honor of National #HeartRecoveryAwarenessDay, there are more than 10 heart recovery reunions taking place this month, celebrating more than 50 patients across the country. Additionally, many patients will be sharing their stories of heart recovery at community and educational events, including the annual Utah Cardiac Recovery Symposium- #UCARS25!
It’s Heart Recovery Day today! Working at Johnson & Johnson MedTech Heart Recovery has shaped my perspective; awareness is critically important, and recovery is possible. Watch inspiring recovery stories here:
abiomed.com/en-us/patients-a…
#HeartRecoveryDay
Michelle Merchant retweeted
First publication of Recover III led by @IvanHansonMD @DrCindyGrines @PerwaizMeraj @BurkhoffMd @AlexandraLansky @SrihariNaiduMD @NavinKapur4 @BillONeillMD
ahajournals.org/doi/10.1161/…
Michelle Merchant retweeted
Today Abiomed celebrates 300,000 Impella patients treated!
This is another important milestone our our journey to make heart recovery the global standard of care, and highlights the impact of our mission.
Michelle Merchant retweeted
Fellows! Don't miss this Saturday's @CRT_meeting virtual Fellows Boot Camp -MECHANICAL SUPPORT FOR PCI | SHOCK - featuring a hands-on demonstration of Impella CP from @HashimHayder.
Register: crtvirtual.org/july-15-2023
Michelle Merchant retweeted
Abiomed's Clinical Care App provides key resources health care professionals can access pre- and post-procedure at the point of care from the cath lab, ICU, OR or while in transport to improve patient outcomes. Download the new Impella® App: heartrecovery.com/impella-ap…
Michelle Merchant retweeted
As #HeartMonth comes to an end, Abiomed would like to thank our patients for being our inspiration.
Abiomed and its employees are committed to recovering hearts, saving lives, and always putting #PatientsFirst - on #HeartMonth and every month!
Michelle Merchant retweeted
Despite pharmalogical support, 10.1% of adults undergoing cardiac surgery develop Low Cardiac Output Syndrome, which can increase the risk of mortality by 12 to 25-fold. Learn about Impella 5.5's potential to reduce the severity for these patients:
abiomed.info/3IYjT7P
Michelle Merchant retweeted
ICYMI - Today Abiomed enters a new and exciting era as part of Johnson & Johnson MedTech.
Learn how this will accelerate our timeline to make heart recovery the global standard of care. #JNJMedTechProud
abiomed.info/3G9tDKC
Michelle Merchant retweeted
Johnson & Johnson is excited to announce that today it completed its acquisition of @Abiomed, bringing a world-leading solution for heart recovery into our portfolio. Learn more here: bit.ly/3PK29hV #JNJ #Cardiovascular